Wells Fargo lowered the firm’s price target on iTeos Therapeutics (ITOS) to $16 from $17 and keeps an Overweight rating on the shares. The firm says there was “not much new” on the company’s update given iTeos continues in execution mode. Wells believes belrestotug’s data could be informative and the update for EOS-984 in the second half of 2025 could be a catalyst at these levels given it is a novel target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- iTeos Therapeutics: Buy Rating Affirmed Amid Promising Pipeline and Strong Financial Position
- iTeos Therapeutics reports Q1 EPS (80c), consensus (90c)
- iTeos Therapeutics: Poised for Success with Anti-TIGIT Therapies Amidst Competitive Landscape
- iTeos Therapeutics price target lowered to $17 from $19 at Wells Fargo
- Promising Developments and Strategic Updates Drive Buy Rating for iTeos Therapeutics